Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)

NCT02858362 is registered in ClinicalTrials.gov with Summit Therapeutics as lead sponsor.

NCT NCT02858362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Lead sponsor
Summit Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2016
Completion date
September 11, 2018
Enrollment
43 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy